Trial · NCT05680818
Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1
NCT05680818, Phase 3, Active not recruiting, Calcilytix Therapeutics, Inc., a BridgeBio company
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1. Trials, record NCT05680818. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05680818
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1
- NCT number
- NCT05680818
- Status
- Active not recruiting
- Phases
- Phase 3
- Enrollment
- 67 participants, actual
- Lead sponsor
- Calcilytix Therapeutics, Inc., a BridgeBio company
- Conditions
- Autosomal Dominant Hypocalcemia (ADH)
- Interventions
- Encaleret, Standard of Care
- First posted
- 2023-01-11
- Last updated
- 2026-07-29
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Responders who Achieve Both Albumin-Corrected Blood Calcium (cCa) and 24-hour Urinary Calcium (UCa) Within the Target Range | Up to Week 24 | * cCa within 8.3-10.7 mg/dL (2.08-2.68 millimoles per liter \[mmol/L\]) * 24-hr UCa within the reference range (\< 300 mg/day for men \[7.5 mmol/day\], \< 250 mg/day for women \[6.25 mmol/day\]) |
| Secondary | Number of Participants With Intact Parathyroid Hormone (iPTH) Within or Greater than the Reference Range | Up to Week 24 | |
| Secondary | Number of Participants who Achieve Blood Magnesium Within the Reference Range | Up to Week 24 | |
| Secondary | Number of Participants who Achieve Blood Phosphate Within the Reference Range | Up to Week 24 | |
| Secondary | Change From Baseline in Blood 1,25-(OH)2 Vitamin D | Baseline to Week 24 | |
| Secondary | Change From Baseline in cCa | Baseline to Week 24 | |
| Secondary | Change From Baseline in 24-hour UCa | Baseline to Week 24 | |
| Secondary | Change From Baseline in iPTH | Baseline to Week 24 | |
| Secondary | Change From Baseline in Blood Phosphate and Blood Magnesium | Baseline to Week 24 | |
| Secondary | Change From Baseline in Urine Magnesium, Phosphate, Sodium, and Citrate Handling | Baseline to Week 24 |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05680818
GET https://conductscience.org/api/trials/v1/NCT05680818/registered